FDA Approves Bydureon Add-On Therapy for Adults With Type 2 Diabetes

April 3, 2018. The US Food and Drug Administration has approved the use of Bydureon—extended-release exenatide—as add-on therapy to basal insulin in adults with type 2 diabetes (T2D) with poor glycemic control. This expanded indication is based on data from the DURATION-7 study, which evaluated Bydureon vs placebo as add-on therapy to insulin glargine in patients with T2D. In this study, mean A1C was reduced by 0.9% in the Bydureon group compared with 0.2% in the placebo group; similar rates of hypoglycemia were reported for both groups. Follow this link to read a detailed summary and this link to the DURATION-7 study abstract.